Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
about
Association between extent of thiazolidinedione exposure and risk of acute myocardial infarctionThe effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.The management of type 2 diabetes mellitus in children and adolescents.Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesGender-specific differences in PPARγ regulation of follicular helper T cell responses with estrogenSex-Based Selectivity of PPARγ Regulation in Th1, Th2, and Th17 Differentiation.Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.Clinical efficacy of a medically supervised outpatient high-protein, low-calorie diet program is equivalent in prediabetic, diabetic and normoglycemic obese patientsRole of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.Sex-specific regulation of immune responses by PPARs.Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism.Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes.Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.Chronic stress and Rosiglitazone increase indices of vascular stiffness in male rats.The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.The long-term effects of rosiglitazone on serum lipid concentrations and body weight.Gender differences in the hepatic elimination and pharmacokinetics of lobeglitazone in rats.Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
P2860
Q28396990-54D7B6CE-DCC3-4FE4-A09A-BF0A6A3FD45EQ35640348-2D9DA1CC-18CB-47E3-9326-ED5A07C48108Q35827821-98B873DC-0374-4239-89AD-595B1304FDC6Q35827919-D11D170B-ED8F-48F0-9998-E20ED10D9F7CQ36063768-D62F61EE-B969-40B5-9C0D-561BA1D375CDQ36684873-99BCB93E-AF8B-483A-9EEB-E48F09A91724Q36812788-5DB7315B-3F18-4E35-B2D1-83199B58D976Q37030803-18ED6BFD-AF5E-4F4B-8D67-EA6DBE2AC13FQ37210221-182F6035-C332-4A26-87B7-BBA0AD418A48Q37600230-6F97AD5A-8A8A-4185-B9B9-11A0A545922CQ37614461-99C725CC-818F-49A0-8018-498FB9662ECCQ37973431-206B3EA5-2899-4293-B861-9320BDE49CD4Q38036773-A0A6A755-1BEE-4BF5-BFD8-3373BE3CED9BQ38393753-3E8F4796-BF9F-4CD9-A9E3-6A1F79D05FEAQ38511039-BCF50A77-CC7F-4FBF-B9B2-DC56CC2C1794Q38641190-EC9257AE-CF22-4ED2-9527-155043685A25Q39624446-CDE6FFEE-9D6F-4046-AB16-5EEA4D7988D1Q40107299-F6567CDB-47F2-445D-AFF9-2789F15A4282Q40326178-1FD40750-B04C-45EC-B3E9-C278C06788B8Q42439893-5CF77F85-DEA3-42E9-AD23-4E054A44486CQ43296443-F717A3E1-49A6-42AF-87FE-F1542B286FCAQ43982800-D2405520-2B7C-4A2C-BAE2-8F0EF8BC53DDQ44580484-980EB224-3A50-4040-8FFB-F3303AC944C4Q45215924-37656048-CCE8-46A1-9A7C-BD48FC55E718Q46137685-4ED264A0-6B18-46EB-8BFE-B0F29117A673Q46545835-380CC6E6-87C5-41AA-BD4F-7EA521FA381FQ47321113-9708109E-4CA8-4AE4-A3B1-ABCE297C1891Q51031198-052334BC-D3C1-4BEB-86E3-A7E76E802364Q51558091-8ACF4E99-A963-40CA-83F4-F3BCF2AD8D79
P2860
Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@en
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@nl
type
label
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@en
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@nl
prefLabel
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@en
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@nl
P2093
P2860
P921
P1476
Rosiglitazone monotherapy impr ...... zed, placebo-controlled study.
@en
P2093
Anderson RJ
Rappaport EB
P2860
P304
P356
10.1046/J.1463-1326.1999.00020.X
P577
1999-05-01T00:00:00Z